Diabetes
New research from the United Kingdom, United States and Italy in the area of diabetes detailed
Published in Obesity and Diabetes Week, September 18th, 2006
Study 1: Treatment with insulin glargine does not suppress serum insulin-like growth factor 1.
"A 6-8-fold higher insulin-like growth factor 1 (IGF-1) receptor binding affinity in vitro is reported for the insulin analogue glargine compared with human insulin. This study evaluates the in vivo significance by exploring the growth hormone (GH)-IGF-1 axis. Assuming a higher binding affinity of insulin glargine to pituitary IGF-1 receptors, serum IGF-1 concentrations should decrease via negative feedback," investigators in England report.
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Adiponectin Receptor
Adiponectin receptor-1 expression increases during weight loss in obese with IGT - Obesity Complications
Obese orthopedic patients have higher postoperative complication and failure rates - Obesity Research
Characteristics of adrenomedullin make it eligible as new adipokine - Obesity Research
Research confirms the human body strongly resists attempts to lose weight - Obesity Therapy
Sitagliptin improved dipeptidyl peptidose-IV activity and glucagons-like peptide-1 in obese - Adverse Drug Reaction
Adverse responses to rosiglitazone in type 2 diabetes model can be predicted by genetics - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
